Q1 FY27 results: Revenue declines 17% YoY, loss widens
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 13.8 pts less than Nifty Microcap 250 and 13.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Gujarat Terce Laboratories reported Q1 FY27 revenue of 900.24 lakh, down about 17% from 1085.36 lakh in Q1 FY26. Total expenses of 963.35 lakh exceeded total revenue, leading to a loss before tax of 14.88 lakh versus 7.10 lakh loss last year. Net loss widened to 17.81 lakh from 4.35 lakh, with EPS at minus 0.23 versus minus 0.06. The statutory auditor issued an unmodified limited review report.
Second straight quarter of losses with shrinking revenue and expenses exceeding income signals operational pressure. Investors should watch for margin recovery.